Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03001219 · ClinicalTrials.gov registry record · Phase 2
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT03001219 is a Phase 2 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 109 participants.
The verdict
NCT03001219, a Phase 2 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
This is a Phase IIa/b double-blind, placebo-controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of RO7123520 as adjunctive therapy in participants with RA who are inadequately responding to standard-of-care (methotrexate and anti-TNF-alpha therapy). Part 1 of the study will evaluate safety. Part 2 will evaluate efficacy and safety. Part 3 will evaluate dose-ranging efficacy. Participants will have the option of continuing to the extension period of the study.
Interventions
- DRUG Placebo
- DRUG Methotrexate
- DRUG Anti-TNF-alpha
- DRUG RO7123520
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2018-11-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03001219
The ClinicalTrials.gov registry entry for NCT03001219 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03001219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03001219 about?
NCT03001219 is a clinical study titled "A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy". This is a Phase IIa/b double-blind, placebo-controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of RO7123520 as adjunctive therapy in participants with RA who are inadequately responding to standard-of-care (methotrexate and anti-TNF-alpha therapy). Part 1 o...
What is the current status of trial NCT03001219?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2016-12-22. Estimated completion is 2018-11-06.
What interventions are being tested in trial NCT03001219?
The interventions under investigation include: Placebo (DRUG), Methotrexate (DRUG), Anti-TNF-alpha (DRUG), RO7123520 (DRUG).
Who is sponsoring clinical trial NCT03001219?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.